Objectives. To identify patients with severe extra-articular RA (ExRA) in an early RA cohort and to investigate potential risk factors. Methods. From a cohort (n ¼ 2900) in a structured programme for newly diagnosed RA, 40 patients with severe ExRA after RA diagnosis were identified. Disease activity score (DAS28), functional disability (HAQ) and treatment with glucocorticosteroids (GCs) and DMARDs were assessed regularly. Cases with ExRA were compared with RA controls from the same cohort matched for age, sex and duration of symptoms at inclusion. Results. Patients who developed severe ExRA were more often current smokers and had higher mean DAS28, HAQ and CRP at baseline. Among the ExRA cases, 93% had a positive RF vs 59% of the controls. The area under the curve (AUC) of DAS28 odds ratio (OR) 7.79/S.D.; 95% CI 3.04, 19.95, HAQ (OR 2.30/S.D.; 95% CI 1.37, 3.88) and CRP (OR 3.05/S.D.; 95% CI 1.77, 5.26) during the first 2 years of follow-up were strong predictors of subsequent development of ExRA. The most frequently used DMARDs were MTX and SSZ, with similar frequency and duration of treatment among cases and controls. The cases were treated with GC before onset of ExRA more frequently (73 vs 47%; P ¼ 0.005) and with higher mean cumulative dose (3667 vs 2037 mg, P ¼ 0.015). Conclusions. High levels of disease activity and disability during the first 2 years after RA diagnosis, smoking and RF predict the development of severe extra-articular RA.
Introduction
RA is a common inflammatory disease that effects 0.5-1.0% of the adult population [1] . The disease process is not only restricted to the joint and its associated structures, but is also associated with the development of extra-articular disease [2, 3] . Extraarticular RA (ExRA) manifestations are of clinical importance because of the associated morbidity and increased risk of premature mortality compared with RA in general [4] [5] [6] [7] [8] . Severe ExRA, including RA-associated lung disease and vasculitis, occurs both in patients recently diagnosed with RA and in those with long-standing disease [5, 6] . Epidemiological and casecontrol studies have suggested that smoking is an important risk factor for RA [9] [10] [11] [12] particularly RF-positive RA [13] [14] [15] , as well as a predictor of severe disease [16] [17] [18] including extra-articular manifestations [19, 20] . In longstanding RA, smoking and early disability have been reported to be independent risk factors for ExRA [21] . Extra-articular manifestations in early RA cohorts have not been extensively studied and the relation between early disease activity and ExRA is unknown.
The aims of the present study were to identify patients with ExRA in an early RA cohort and to investigate potential risk factors, including smoking and the burden of disease activity.
Patients and methods
The patients were recruited from the BARFOT (Better AntiRheumatic FarmacOTherapy) register, which is a structured programme for follow-up of newly diagnosed RA [22] . The BARFOT register was established in September 1992 and the patients have been followed up until September 2006 (median follow-up 91 months; range 6-156 months). Of the participating six outpatient rheumatology clinics, five are located in the south and west of Sweden (at the general hospitals in Helsingborg, Kalmar, Kristianstad, Mo¨lndal and the Spenshult Hospital for Rheumatic Diseases) and one clinic in the southern part of the Stockholm area (Karolinska University Hospital at Huddinge). General practitioners in these areas are strongly recommended to refer patients with RA or suspected RA to specialized rheumatology examination early in the disease.
At the first visit, patients reported the duration of symptoms which is documented by the rheumatologist. If the symptoms of arthritis (swollen joints) lasted for 412 months the patients were included in the BARFOT register. A detailed history was obtained using a structured questionnaire including smoking history (smoker, ex-smoker and never smoked). Joints (28 joints index) were examined for the presence of soft tissue swelling and/or tenderness, and the disease activity score (DAS28) [23] was calculated. The presence of rheumatoid nodules was recorded and patients completed the Swedish validated version of the HAQ [24] . ESR, CRP and RF were measured at the local laboratory. Measurements of RF titres were not available.
The patients in the register also must meet at least four of seven items from the 1987 ACR classification criteria for RA [25] to be included. The register covers virtually all adults (aged 516 years) who were registered with a rheumatologist in one of the six regions, corresponding to a population of $1.5 million, predominantly of European Caucasoid origin.
The patients have been examined regularly and their disease including extra-articular manifestations has been characterized. Pharmacological treatments [glucocorticosteroids (GCs) and DMARDs] have been reported at each visit; after 3 and 6 months, every sixth month up to 4 years and thereafter annually. All patients gave their informed consent to participate in the study. The study was approved by the research ethics committee of Lund University, and was carried out according to the Declaration of Helsinki.
Cases and controls
The study design was a nested case-control investigation. From a cohort (n ¼ 2900) in the BARFOT register a total of 113 patients with ExRA reported by the physicians were identified. Medical records were reviewed for all cases and the extra-articular manifestations were classified according to pre-defined criteria (Table 1 ) [26] . Sixty-one cases out of 113 were excluded as the diagnosis was incorrect or the case record did not contain enough data to support the diagnosis. Fifty-two cases fulfilled the criteria. Patients with a known history of extra-articular manifestations after the onset of arthritis symptoms, but before inclusion in the RA register (n ¼ 12; 10 men and 2 women) were also excluded. Consequently, the group with severe ExRA after RA diagnosis consisted of 40 patients. For each case, three controls (n ¼ 120) were selected from the same cohort. Cases and controls were matched for age (AE5 years), sex and duration of symptoms at inclusion (AE5 months). The medical records of the controls were reviewed in order to ensure that they did not have a history of ExRA during the follow-up period.
Statistical analysis
Data were analysed using the SPSS software (SPSS 12.0). Odds ratios (OR) with 95% CI were calculated for smoking and high (DAS28 > 5.5) vs low to moderate (DAS28 4 5.5) disease activity using conditional logistic regression models, taking into account the matched design of the study. The cut-off score of 5.5 for high disease activity was chosen according to the study defining validated criteria for disease activity states reported by Aletaha and co-workers [27] .
The accumulated disease burden during the first 2 years was calculated as the area under the curve (AUC) for DAS28, HAQ and CRP. For cases who developed ExRA within 2 years from inclusion, the AUC was based on observations prior to ExRA onset. For comparability of different measures of disease burden, ORs for ExRA were calculated per S.D. of DAS28, HAQ and CRP AUCs.
The use of GC and MTX was calculated as number of months ever used from the first visit to the development of ExRA. Disease activity and disability AUCs and time on GC or MTX was handled similarly for the controls (i.e. each control was censored when the corresponding case developed ExRA).
Results
Identified ExRA manifestations are shown in Table 2 . There was a predominance of RA-associated interstitial lung disease (n ¼ 18) and pleuritis (n ¼ 6).
There were 29 women and 11 men among the ExRA patients. Age and disease duration were similar among cases and controls due to matching. ExRA patients were more often current smokers and the controls had more often never smoked at the time of diagnosis (Table 3 ). The median date of inclusion in the BARFOT register was April 1998 [interquartile range (IQR): from February 1996 to September 2000] for cases, and October 1997 (IQR: from March 1996 to June 1999) for controls. The mean age at the time of first presentation of ExRA was 61 years (median 61 years; range 39-86 years). The mean duration of RA at onset of ExRA was 30 months (median 25 months; range 2-121 months). The cases more often had a positive RF (93 vs 59%) and rheumatoid nodules at first visit were more common among the cases (Table 3) .
Pharmacological treatment
A majority of the patients started with pharmacological treatment (GC or DMARDs) at the first visit (80% of the cases, 79% of the controls) and continued with active treatment during the followup visits. The most frequently used DMARDs were SSZ and MTX among both cases and controls. The cases were more often on treatment with GC, other DMARDs than SSZ and MTX and with combinations (Table 3) . Other DMARDs included auranofin, sodium aurothiomalate, AZA, anti-malarials, cyclophosphamide, cyclosporin and LEF. Only six patients (three cases, three controls) were treated with biologics. No patient had been treated with GC or DMARDs before inclusion.
The mean daily GC doses were higher among the cases with GC for longer periods, and the mean cumulative dose of GC was higher for the cases (Table 3) .
Disease activity, disability and smoking
Patients who later developed ExRA demonstrated higher mean CRP values as well as higher scores for both DAS28 and HAQ at baseline ( The associations between disease activity and disability burden during the first 2 years and subsequent ExRA remained significant in models adjusted for current smoking at baseline and GC treatment (ever vs never) (Fig. 1) .
Discussion
In this nested case-control study from a large RA inception cohort, high early disease activity and disability, smoking and positive RF were associated with an increased risk of severe ExRA manifestations. The DAS28 AUC during the first 2 years from diagnosis was a strong predictor, indicating that patients with persistently high disease activity are at particular risk of severe ExRA.
Our findings are in accordance with a previous communitybased study, in which early disability was a predictor of subsequent ExRA in patients with RA onset between 1955 and 1995 [21] . The present study extends these observations to RA patients identified between 1992 and 2005, who were treated with DMARDs and GCs from diagnosis according to modern rheumatology practice. However, only six patients were on biologics (three cases and three controls) as the main period for follow-up was before the treatment with biologics was more widely available for early RA. Before January 2000, 75% of the patients were included in the register and the mean duration between RA diagnosis and ExRA onset was 30 months.
There was a predominance of females among the cases, which is not consistent with others, but data are conflicting [26] . Among the 12 patients with ExRA at the first visit, who were excluded from the present analysis, there was a predominance of men (10 men and 2 women).
These observations should be interpreted with caution, given the limited sample size.
To make the cases and controls more comparable they were matched for age, sex and duration of symptoms at inclusion in the register. ExRA is a rare condition, and to increase the statistical power of the study three controls were matched with each case.
Other studies have also found smoking to be a predictor of vasculitis [28, 29] and severe ExRA overall [21, 29] . We have previously reported an association between ever smoking and rheumatoid nodules at disease onset in the BARFOT early RA cohort [30] . In contrast, the increased risk of severe ExRA in the present sample was restricted to current smokers at inclusion and not statistically significant for former-smokers.
Tobacco smoking is the environmental factor that has most consistently been identified to have adverse effects on RA. Studies have suggested that individuals who smoke are more likely to develop RA [9, 12, [31] [32] [33] [34] , and that patients with RA who smoke are more likely to have more severe disease [16, 18, 35, 36] . The strongest association between smoking and RA has been reported for those with seropositive RA [14] .
In accordance with previous studies, which have shown that RF is predictive of more severe disease [13] [14] [15] [16] , we found a greater proportion of RF-positive patients among those who developed ExRA. Studies of patients with active severe extra-articular disease have shown high levels of RF, suggesting that RF contribute to the pathogenesis of ExRA [37] . Analysis of antibodies to cyclic citrullinated peptides (anti-CCP) were not performed for the majority of the patients in this cohort established in 1992. It has previously been shown that anti-CCP and RF are strongly associated [37] in ExRA patients. Analysis of anti-CCP would probably not have given any further information as 76% of the RA patients were RF positive.
A majority of the patients received active drug treatment with GC and DMARDs. The cases were more often on treatment with GC and had more frequently combination therapy, indicating a more severe and treatment-resistant disease phenotype. Since they had higher cumulative disease activity, our study supports the concept that poorly controlled early RA is associated with adverse long-term outcomes, and provides yet another rationale for aggressive treatment, including biologics, in patients with persistent disease activity. Furthermore, our data suggest a role for long-term effects of inflammation in the development of extraarticular organ involvement in RA. Potential mechanisms include systemic immunomodulation or tissue damage associated with chronic inflammation.
Limitations of the present study are mainly due to the small sample size. Predictors may vary for different ExRA manifestations, but the study is not powered to address this issue. The limited sample size is partly due to the fact that only ExRA manifestations reported to the register were studied. It is quite possible that a number of patients who developed ExRA were not reported and thus not reviewed. Another limitation is the use of ACR criteria, which may lead to exclusion of some patients since these are not reliable for classifying RA during the early stages of RA disease. However, the extent of such under reporting and its impact on the prediction models cannot be estimated.
Another limitation of the study is the lack of information about radiographic damage. Only 50% of the patients (18 cases and 62 controls) had radiographs available for analysis and this was considered to be too small a sample size for computation of robust association with ExRA.
The main strength of the study is the follow-up programme, with repeated assessments at regular time intervals, which enables analysis of the effect of disease burden over time. This is a major advantage of using samples from inception cohorts for the study of long-term outcomes.
In summary, this study indicates that current smoking, high disease activity at RA onset and RF seropositivity are risk factors for severe ExRA early in the disease course. Continuous high levels of disease activity and disability during the first 2 years after RA diagnosis predicted the development of severe ExRA. Although not formally comparing different treatment strategies, these results support the importance of decreasing disease activity extensively in patients with early RA. Since the clinical course of RA is highly variable, further studies should aim at defining prognostic markers that could identify patients at risk for poor outcome and guide treatment strategies.
